Imunon (IMNN) investor relations material

Executive summary

• IMNN-001 demonstrated a 14.7-month median overall survival benefit in Phase II OVATION 2 for advanced ovarian cancer, with even greater benefit (24.2 months) when combined with PARP inhibitors.

• Enrollment in the pivotal Phase III OVATION 3 trial is progressing ahead of plan, with completion expected by Q1 2029.

• FDA has reviewed and aligned with the Phase III protocol, confirming the path to BLA filing.

• Strategic reorganization completed in Q1 2026 aims to optimize resources, reduce operating expenses, and support OVATION 3 advancement.

• Focus remains on disciplined execution, cash conservation, and advancing IMNN-001 toward regulatory milestones.

Financial highlights

• Net loss for Q1 2026 was $4.3 million ($0.84 per share), compared to $4.1 million ($3.15 per share) in Q1 2025.

• Research and development expenses increased to $2.3 million from $2.2 million year-over-year, reflecting OVATION 3 trial initiation.

• General and administrative expenses were stable at $2.2 million in Q1 2026 compared to Q1 2025.

• Net cash used in operating activities was $4.0 million for Q1 2026, up from $2.8 million year-over-year, mainly due to trial-related costs.

• Cash and cash equivalents stood at $4.8 million as of March 31, 2026, down from $8.8 million at year-end 2025.

Outlook and guidance

• On track to randomize approximately 80 patients in OVATION 3 by end of Q1 2027; full enrollment of 500 patients expected by Q1 2029.

• Two interim analyses planned for the Phase III trial, with potential for early stopping for efficacy.

• R&D Day event planned for Q3 2026 to present final OVATION 2 efficacy and new translational data.

• Management has substantial doubt about the ability to continue as a going concern without additional capital.

• Plans include raising funds through equity offerings, partnerships, and cost reductions.